Company intelligence / Profile preview

Nantong Bencao Quadriga Medical Technology Co. Ltd.

Ownership: Private
Development stage: Phase 2

Overview

The company is currently conducting Phase 2 clinical trials for NBQ72S in patients with leptomeningeal metastases from breast cancer. Previous studies have shown that QBS72S (likely the same as NBQ72S) can cross the blood-brain barrier and exhibits potential for cytotoxicity with a mechanism distinct from temozolomide with low off-target effects.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NBQ72S

Phase 2

Indications: Breast cancer with leptomeningeal metastasis

Beyond the preview

Go deeper on Nantong Bencao Quadriga Medical Technology Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nantong Bencao Quadriga Medical Technology Co. Ltd..

Explore the full profile